See more : Aspira Pathlab & Diagnostics Limited (ASPIRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Carisma Therapeutics, Inc. (CARM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carisma Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Latrobe Magnesium Limited (LMG.AX) Income Statement Analysis – Financial Results
- Unick Fix-A- Form and Printers (UNICK.BO) Income Statement Analysis – Financial Results
- Pinstripes Holdings Inc. (PNST) Income Statement Analysis – Financial Results
- Chemours Co (2CU.DE) Income Statement Analysis – Financial Results
- ApartmentLove Inc. (APLV.CN) Income Statement Analysis – Financial Results
Carisma Therapeutics, Inc. (CARM)
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.92M | 9.83M | 26.54M | 11.24M | 0.00 | 0.00 | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Cost of Revenue | 74.13M | 6.09M | 85.00K | 0.00 | 219.00K | 208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.21M | 3.74M | 26.46M | 11.24M | -219.00K | -208.00K | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Gross Profit Ratio | -396.85% | 38.07% | 99.68% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 74.13M | 56.62M | 34.39M | 23.29M | 24.44M | 13.87M | 12.23M | 12.20M | 25.97M | 26.70M | 13.79M | 15.26M | 9.41M |
| General & Administrative | 29.53M | 9.38M | 6.41M | 5.09M | 12.21M | 11.62M | 8.07M | 14.74M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Selling & Marketing | 0.00 | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | -170.00K | -3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.53M | 3.29M | 6.41M | 5.09M | 12.21M | 11.62M | 7.90M | 11.44M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.65M | 59.91M | 40.79M | 28.38M | 36.65M | 25.49M | 20.13M | 23.64M | 35.82M | 35.17M | 17.81M | 19.48M | 12.68M |
| Cost & Expenses | 103.65M | 66.00M | 40.79M | 28.38M | 36.87M | 25.70M | 20.41M | 23.82M | 36.19M | 35.17M | 17.81M | 19.48M | 12.68M |
| Interest Income | 1.94M | 1.85M | 10.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 247.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Depreciation & Amortization | 2.84M | 6.09M | 85.00K | 122.00K | 219.00K | 208.00K | 285.00K | 178.00K | 366.00K | 410.00K | 438.00K | 448.00K | 364.00K |
| EBITDA | -85.89M | -51.99M | -40.11M | -27.93M | -107.28M | -33.49M | -28.74M | 2.32M | -31.69M | -33.37M | -17.18M | -19.04M | -12.31M |
| EBITDA Ratio | -575.74% | -509.17% | -151.12% | -248.58% | 0.00% | 0.00% | -4,635.29% | 21.16% | -3,518.18% | -1,487.74% | -1,213.42% | 0.00% | 0.00% |
| Operating Income | -88.73M | -56.16M | -40.79M | -28.38M | -36.87M | -25.70M | -19.99M | 6.17M | -35.20M | -33.78M | -16.63M | -19.49M | -12.68M |
| Operating Income Ratio | -594.75% | -571.10% | -153.68% | -252.56% | 0.00% | 0.00% | -4,702.35% | 20.57% | -3,555.15% | -1,506.02% | -1,246.25% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.85M | -5.06M | 10.00K | 29.00K | -70.63M | -7.99M | -9.04M | -4.27M | 1.74M | -1.23M | -1.40M | -168.00K | -151.00K |
| Income Before Tax | -86.88M | -61.23M | -40.78M | -28.35M | -107.50M | -33.69M | -29.03M | 1.90M | -33.45M | -34.16M | -18.03M | -19.66M | -12.83M |
| Income Before Tax Ratio | -582.34% | -622.60% | -153.65% | -252.31% | 0.00% | 0.00% | -6,830.35% | 6.32% | -3,378.99% | -1,522.78% | -1,351.20% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.88M | -10.00K | -29.00K | 0.00 | 46.86K | 0.00 | 5.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Net Income | -86.88M | -61.23M | -40.77M | -28.32M | -107.50M | -33.69M | -29.03M | 1.89M | -33.45M | -34.53M | -19.43M | -19.83M | -12.98M |
| Net Income Ratio | -582.34% | -622.60% | -153.61% | -252.05% | 0.00% | 0.00% | -6,830.35% | 6.31% | -3,378.99% | -1,539.55% | -1,456.15% | 0.00% | 0.00% |
| EPS | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.79 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| EPS Diluted | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.74 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| Weighted Avg Shares Out | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.05M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
| Weighted Avg Shares Out (Dil) | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.09M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/...
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatility when entering this arena.
Carisma Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at several upcoming investor conferences, including: H.C.
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in...
Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know
The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company's collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash,...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on...
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes
PHILADELPHIA , June 26, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will join the Russell 2000®, Russell 3000® and...
Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources
These new appointments expand the leadership team to support its legal and human resource sectors to ensure compliance and high quality employee experience PHILADELPHIA , June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"),...
Source: https://incomestatements.info
Category: Stock Reports